OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Publication Date
Release Date
2025
(3)
2021
(3)
2023
(2)
2024
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Effects of climate variables on the transmission of COVID-19: a systematic review of 62 ecological studies.
Not available
S-EPMC8364942
|
biostudies-literature
Cite
Safety and efficacy of PD-1 antibody combined with pegylated interferon α for functional cure in nucleos(t)ide analogues-suppressed chronic hepatitis B patients: protocol for a multicentre randomised controlled trial.
Not available
S-EPMC12458774
|
biostudies-literature
Cite
Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon.
Not available
S-EPMC12715036
|
biostudies-literature
Cite
Improved esophageal squamous cell carcinoma screening effectiveness by risk-stratified endoscopic screening: evidence from high-risk areas in China.
Not available
S-EPMC8360639
|
biostudies-literature
Cite
APOBEC3B coordinates R-loop to promote replication stress and sensitize cancer cells to ATR/Chk1 inhibitors.
Not available
S-EPMC10239489
|
biostudies-literature
Cite
Cytosine base editors induce off-target mutations and adverse phenotypic effects in transgenic mice.
Not available
S-EPMC10063651
|
biostudies-literature
Cite
Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers.
Not available
S-EPMC12281707
|
biostudies-literature
Cite
Deep learning models incorporating endogenous factors beyond DNA sequences improve the prediction accuracy of base editing outcomes.
Not available
S-EPMC10879117
|
biostudies-literature
Cite
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Not available
S-EPMC8441057
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets